Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

52.04
-1.4000-2.62%
Pre-market: 52.990.9500+1.83%07:57 EDT
Volume:1.65M
Turnover:85.89M
Market Cap:4.91B
PE:-109.22
High:53.44
Open:53.44
Low:51.45
Close:53.44
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.62
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:200.04
PE(LYR):-181.73

Loading ...

Travere Therapeutics - Everest to Receive $112.5 Mln Upfront for Civorebrutinib Rights

THOMSON REUTERS
·
Jun 02

Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines for Civorebrutinib a Potential Best-in-Class Btk Inhibitor for Rare Kidney Diseases

THOMSON REUTERS
·
Jun 02

Travere Therapeutics - Everest Eligible for up to $1.03 Bln in Additional Milestone Payments

THOMSON REUTERS
·
Jun 02

Why Travere Therapeutics (TVTX) Is Up 6.2% After New FILSPARI IgA Nephropathy Patent Protection

Simply Wall St.
·
Jun 02

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

Simply Wall St.
·
May 29

Travere confirms Notice of Allowance from USPTO for Filspari patent application

TIPRANKS
·
May 28

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX)

TIPRANKS
·
May 28

Travere Therapeutics wins USPTO allowance for FILSPARI IgA nephropathy use patent application

Reuters
·
May 28

Travere Therapeutics - to Submit Issued Filspari Patent for Orange Book Listing

THOMSON REUTERS
·
May 28

Travere Therapeutics Receives Notice of Allowance From the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using Filspari® (Sparsentan) in Iga Nephropathy

THOMSON REUTERS
·
May 28

Travere Therapeutics - Patent Expected to Provide U.S. Coverage for Filspari in Iga Nephropathy Into October 2037

THOMSON REUTERS
·
May 28

Travere Therapeutics raises 2018 equity plan share reserve to 25,384,114 shares

Reuters
·
May 22

Travere Therapeutics Director Timothy Coughlin sells 3,250 shares for $141,342.50

Reuters
·
May 20

Three Companies Priced Below Estimated Value In May 2026

Simply Wall St.
·
May 19

3 Stocks Possibly Trading Below Estimated Value

Simply Wall St.
·
May 13

Travere Therapeutics grants inducement equity awards covering 48,800 shares to new hires

Reuters
·
May 13

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 13

Travere Therapeutics plans offering of $400 million convertible senior notes due 2032

Reuters
·
May 12

Travere Therapeutics Inc - Offers $475 Mln of 0.50% Convertible Senior Notes Due 2032 - SEC Filing

THOMSON REUTERS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08